NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced it will release financial results for its fiscal second quarter ended March 31, 2026, before market open on Tuesday, May 12, 2026. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time that day to discuss the results, provide a corporate update, and answer questions from telephone participants.
The earnings call will be accessible via U.S. toll-free dial-in at 888-506-0062 or international dial-in at 973-528-0011, using participant access code 224785. A live webcast will also be available through the company's investor relations page at newmediawire.com. Participants are encouraged to join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through Tuesday, May 26, 2026, by calling 877-481-4010 (U.S.) or 919-882-2331 (international) with replay passcode 53948. A webcast replay will also be accessible via the same link through Wednesday, May 12, 2027.
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For business leaders and investors, this earnings release is a key indicator of the company's financial health and progress in the medical technology sector. NeuroOne's focus on minimally invasive solutions for neurological disorders positions it in a growing market driven by aging populations and increasing demand for advanced surgical options. The company's performance in Q2 may reflect adoption rates of its FDA-cleared products and progress in its R&D pipeline.
The call will provide insights into revenue trends, operational milestones, and strategic direction. Given the competitive landscape of medical devices, particularly in neuromodulation and ablation, NeuroOne's ability to execute on its commercial strategy and advance new programs will be closely watched. The company's stock performance and future outlook could influence investor sentiment in the broader medtech industry.
For more information about NeuroOne and its technologies, visit nmtc1.com.
